BDP5290 |
| Katalog-Nr.GC32868 |
BDP5290 ist ein potenter Inhibitor sowohl von ROCK als auch von MRCK mit IC50-Werten von 5 nM, 50 nM, 10 nM und 100 nM fÜr ROCK1, ROCK2, MRCKα bzw. MRCKβ.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1817698-21-7
Sample solution is provided at 25 µL, 10mM.
BDP5290 is a potent inhibitor of ROCK and MRCK with IC50 values of 17nM, 230nM, 123nM and 100nM for MRCKβ, ROCK1, ROCK2, respectively [1].
BDP5290 (2 µM, 24h) treated ATII cells decreased baseline TEER, and prevented the β1 subunit-induced increase of barrier integrity [2]. 3 µM BDP5290 completely inhibited MLC phosphorylation induced by MRCKβ, but not by ROCK1 or ROCK2 [1]. BDP5290 treated parental MDA-MB-231 breast cancer cells at varying concentrations, and showed endogenous MRCK and ROCK inhibition effect of pMLC with EC50 of 316 nM [1]. application of 0.5 µM BDP5290 lessened both cytoplasmic and cortical pMLC levels in MDA-MB-231 cells [1]. BDP5290 reduced MDA-MB-231 invasion at concentrations starting from 0.1 µM, with virtually complete inhibition at 10 µM [1]. 2-µM BDP5290 strongly inhibited the ability of human SCC12 squamous cell carcinoma cells to invade a 3D collagen matrix [1].
References:
[1]. Unbekandt M, Croft D R, Crighton D, et al. A novel small-molecule MRCK inhibitor blocks cancer cell invasion[J]. Cell Communication and Signaling, 2014, 12(1): 1-15.
[2]. Bai H, Zhou R, Barravecchia M, et al. The Na+, K+-ATPase β1 subunit regulates epithelial tight junctions via MRCKα[J]. JCI insight, 2021, 6(4).
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *